NCT07177092 (SURGAN-TKI) is a Phase 2 clinical trial of Surgery in Non-Small Cell Lung Cancer, sponsored by Jianxing He.

Who is sponsoring NCT07177092?

NCT07177092 is sponsored by Jianxing He.

What drugs are being tested in NCT07177092?

Interventions in NCT07177092: Surgery, Osimertinib.

What condition does NCT07177092 study?

NCT07177092 studies Non-Small Cell Lung Cancer, EGFR.

Is NCT07177092 still recruiting?

NCT07177092 is currently not yet recruiting. Last updated 16 September 2025.

Last reviewed 2025-09-16 · How we verify

NCT07177092: SURGAN-TKI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer

Not yet recruiting Phase 2 Last updated 16 September 2025

What this trial tests

Phase 2 trial testing Surgery in Non-Small Cell Lung Cancer in 118 participants. Not yet recruiting.

Timeline

8 September 2025

Primary endpoint
1 October 2028

1 December 2030

Quick facts

Lead sponsor	Jianxing He
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	118
Start date	8 September 2025
Primary completion	1 October 2028
Estimated completion	1 December 2030

Drugs / interventions tested

Surgery
Osimertinib (osimertinib) — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →
EGFR — all drugs for EGFR →

Sponsor

Jianxing He — full company profile →

Who can join

Adults 18 to 75, any sex, with Non-Small Cell Lung Cancer or EGFR. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to explore whether resecting the primary lung cancer, followed by osimertinib, can improve outcomes for patients with advanced non-small cell lung cancer (NSCLC) harboring sensitizing EGFR mutations (exon 19 deletion or L858R). Patients with stage III-IV NSCLC will be included and randomly assigned to receive either surgery to remove the primary lung cancer followed by osimertinib, or osimertinib alone. All patients will continue treatment until disease progression or they need to stop for another reason. The primary outcome being studied is progression-free survival (PFS). Secondary outcomes include overall survival (OS), objective response rate (ORR), disease control rate (DCR), adverse effects (AEs), serious adverse effects (SAEs) and quality of life (QoL). The findings from this study may help determine whether surgery combined with EGFR tyrosine kinase inhibitor (TKI) provides more benefit than EGFR-TKI alone for patients with EGFR-mutant advanced NSCLC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Surgery

Trials testing the same drug.

NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
NCT07524452 — Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, · Phase 3 · recruiting
NCT07053033 — Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR Be · Phase 2 · recruiting
NCT07352007 — Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular · Phase 2 · not yet recruiting
NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Jianxing He trials

Trials by the same sponsor.

NCT07492342 — Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC · Phase 2 · recruiting
NCT07377123 — Tubeless Spontaneous Ventilation Anesthesia in Kidney Transplantation · NA · not yet recruiting
NCT07177105 — Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC · Phase 2 · not yet recruiting
NCT07110259 — AI-Based DeepGEM Tool for Predicting Gene Mutations in NSCLC Patients: A Randomized Controlled Study · NA · not yet recruiting
NCT07201077 — ArticuGrasp Trial: New Flexible Tool vs Standard Grasper for Lung Cancer Node Removal in Keyhole Chest Surgery · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07177092 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jianxing He
Last refreshed: 16 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07177092.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing